Sonya Wei Song, Born in 1964, Professor of Oncology/Deputy Chair in Brain Tumor Center, Beijing Institute for Brain Disorders, Capital Medical University.

Education:

In 1985, B.S., Biology, Sichuan University, Chengdu, China; In 1996, PhD, Molecular Biology, University of Tennessee, Knoxville, USA; In 1996-1997, Postdoctoral fellow, Neurology, Medical School of Johns Hopkins University, Baltimore, USA.

Professional Affiliations:

Active member in American Association for Cancer Research, Standing committee member of Chinese Anti-cancer Association-Biomarker Subcommittee, Member, Chinese Society for Clinical Oncology; Editorial Board Member in Thoracic Cancer and The Chinese Journal of Lung Cancer; Reviewer for Beijing Science and Technology Awards, Cancer Letters, DNA and Cell Biology, PloS One etc.  

Research Interests and Achievements:

Focus on 1) tumor microenvironment for tumorigenesis and progression, 2) Tumor biomarker discovery for clinical applications. We are dedicated to investigate how tumor immune-microenvironment regulates tumor initiation and progression especially how tumor induces immunosuppressive microenvironment to promote tumor development. Meanwhile, we have been pursuing to identify clinically valuable biomarkers for tumor diagnosis and directing targeted and individualized therapies. Accordingly, we have published more than 30 related articles and been granted three patents including the recent one entitled Combined IGFBP2 and IGFBP2 autoantibody-based tumor diagnosis and its application.  

 
Publications:
1）    Zhang W, Zhang J, Jiang HT, Li SW, Kang C, You Y, Jiang C, Zhang Y, Chen X, He S, Li X, Chen CC,  Song SW*, Jiang T*. Whole-genome microRNA expression profiling identifies a five-microRNA signature as the prognostic biomarker in the Chinese patients with primary glioblastoma multiforme. Cancer 2013 119(4):814-24.
2）    Zhang W, Zhang J, Hoadley K, Kushwaha D, Carter B, Li S, Kang C, You Y, Jiang C, Song SW*, Jiang T*, Chen CC*. miR-181d: a predictive glioblastoma biomarker that down regulates MGMT expression. Neuro-Oncology 2012, 14(6):712-9
3）    Li Y, Jiang T, Zhang J, Zhang B, Yang W, You G, Xu K, Wu J, Luo C, Song SW. Elevated serum IGFBP-2 antibodies allow detecting early stages of cancers. Evidences from glioma and colorectal carcinoma studies. Annals of Oncology 23 (9): 2415-2422, 2012.
4）    Wu Y, Song SW, Sun JY, Bruner JM, Fuller GN, Zhang W. MIIP (IIp45) inhibits cell migration through inhibition of HDAC6. Journal of Biological Chemistry 285: 3554-3560, 2010
5）    Lin Y, Jiang T, Zhou KJ, Xu L, Chen B, Li GL, Qiu XG, Jiang TZ, Zhang W, Song SW. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro-Oncology 11:468-76, 2009.